06
Jan
A fixed-dose combination (FDC) of Sodium-Glucose Co-Transporter Inhibitor (SGLT2i) - Remogliflozin Etabonate and Vildagliptin has been launched by Glenmark Pharmaceuticals Limited in India. The fixed drug combination is indicated for the management of Type 2 diabetes. The combination will contain Remogliflozin (100 mg) + Vildagliptin (50 mg) in a fixed-dose and must be taken twice daily. Glenmark has launched the same under two brand names Remo V and Remozen V. In the world, Glenmark is the first company to launch Remogliflozin + Vildagliptin fixed dose combination and India is the first country to get access to this FDC drug. Glenmark…
